DE60223670T2 - Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen. - Google Patents

Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen. Download PDF

Info

Publication number
DE60223670T2
DE60223670T2 DE60223670T DE60223670T DE60223670T2 DE 60223670 T2 DE60223670 T2 DE 60223670T2 DE 60223670 T DE60223670 T DE 60223670T DE 60223670 T DE60223670 T DE 60223670T DE 60223670 T2 DE60223670 T2 DE 60223670T2
Authority
DE
Germany
Prior art keywords
cells
bone marrow
neutropenia
compound
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60223670T
Other languages
German (de)
English (en)
Other versions
DE60223670D1 (de
Inventor
Lyne Laval GAGNON
Jean Montreal BARABE
Pierre Montreal LAURIN
Christopher Pierrfonds PENNEY
Boulos Laval ZACHARIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Application granted granted Critical
Publication of DE60223670D1 publication Critical patent/DE60223670D1/de
Publication of DE60223670T2 publication Critical patent/DE60223670T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/003—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with alcohols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
    • C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
    • C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60223670T 2001-04-18 2002-04-18 Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen. Expired - Lifetime DE60223670T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28445801P 2001-04-18 2001-04-18
US284458P 2001-04-18
PCT/CA2002/000535 WO2002083120A2 (en) 2001-04-18 2002-04-18 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors

Publications (2)

Publication Number Publication Date
DE60223670D1 DE60223670D1 (de) 2008-01-03
DE60223670T2 true DE60223670T2 (de) 2008-03-06

Family

ID=23090294

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223670T Expired - Lifetime DE60223670T2 (de) 2001-04-18 2002-04-18 Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.

Country Status (30)

Country Link
US (2) US7745488B2 (OSRAM)
EP (2) EP1900364B1 (OSRAM)
JP (3) JP5026655B2 (OSRAM)
KR (1) KR20030096323A (OSRAM)
CN (1) CN1633286A (OSRAM)
AP (1) AP1740A (OSRAM)
AU (2) AU2002308456B2 (OSRAM)
BG (1) BG66418B1 (OSRAM)
BR (1) BR0208984A (OSRAM)
CA (2) CA2444463C (OSRAM)
CY (1) CY1107081T1 (OSRAM)
CZ (1) CZ305273B6 (OSRAM)
DE (1) DE60223670T2 (OSRAM)
DK (2) DK1900364T3 (OSRAM)
EA (1) EA007322B1 (OSRAM)
EE (1) EE200300510A (OSRAM)
ES (2) ES2439738T3 (OSRAM)
HU (1) HUP0303817A3 (OSRAM)
IL (3) IL158322A0 (OSRAM)
MX (1) MXPA03009436A (OSRAM)
NO (1) NO335105B1 (OSRAM)
NZ (2) NZ528690A (OSRAM)
OA (1) OA12506A (OSRAM)
PL (2) PL223348B1 (OSRAM)
PT (2) PT1900364E (OSRAM)
SI (1) SI1385498T1 (OSRAM)
SK (1) SK12772003A3 (OSRAM)
TN (1) TNSN03089A1 (OSRAM)
WO (1) WO2002083120A2 (OSRAM)
ZA (1) ZA200307778B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083120A2 (en) * 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
AP2005003367A0 (en) * 2003-02-07 2005-09-30 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis.
PL1648851T3 (pl) 2003-07-25 2007-09-28 Prometic Biosciences Inc Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami
KR20070044805A (ko) * 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
BRPI0515136A (pt) * 2004-09-03 2008-07-08 Prometic Biosciences Inc derivados de purinila substituìdos com atividade imunomoduladora e quimioprotetora, seus usos isolados ou com ácidos graxos ou glicerìdeos de comprimento de cadeia médio e respectivas composições
EP1804780B1 (en) * 2004-10-01 2011-11-16 ProMetic BioSciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
WO2006090289A2 (en) * 2005-02-28 2006-08-31 Alphabeta Ab Compounds for reducing aggregation of amyloid beta-peptide
JP2009537137A (ja) * 2006-05-17 2009-10-29 コグネート セラピューティクス，インコーポレーテッド 脂肪吸引後の脂肪吸引物からの造血幹細胞の単離および精製
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
CA2704286C (en) * 2007-11-02 2016-08-23 Prometic Biosciences Inc. Medium-chain length fatty acids and glycerides as nephroprotection agents
CA2708679C (en) * 2007-12-19 2016-11-15 Prometic Biosciences Inc. Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
US20090326070A1 (en) 2008-05-01 2009-12-31 Complexa Inc. Vinyl substituted fatty acids
CN102099024B (zh) * 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
JP5623406B2 (ja) 2008-09-17 2014-11-12 キアズマ インコーポレイテッド 医薬組成物および関連する送達方法
EP2165713B1 (en) * 2008-09-19 2012-11-14 Nestec S.A. Whey and thymus function
JP2013500966A (ja) 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
CA2781276A1 (en) 2009-10-02 2011-04-07 Complexa, Inc. Heteroatom containing substituted fatty acids
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
TWI572352B (zh) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
EA029382B1 (ru) * 2012-05-09 2018-03-30 Кантекс Фармасьютикалз, Инк. Лечение миелосупрессии
US20160199338A1 (en) 2013-08-19 2016-07-14 Enzychem Lifesciences Corporation Compositions containing monoacetyldiacylglycerol compound as an active ingredient for preventing or treating rheumatoid arthritis
WO2015176012A1 (en) 2014-05-15 2015-11-19 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
EP3253401B1 (en) 2015-02-03 2025-04-02 Amryt Endo, Inc. Treating acromegaly with oral octreotide
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
CN108430466A (zh) 2015-10-02 2018-08-21 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
CN109069475B (zh) 2016-04-22 2022-01-28 受体控股公司 快速作用植物类医药化合物和营养补剂
KR20190017873A (ko) 2016-06-08 2019-02-20 썬리겐 헬쓰케어 아게 홀수의 탄소 원자를 갖는 지질 및 제약 조성물 또는 영양 보충제로서의 그의 용도
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CN107382710B (zh) * 2017-08-19 2020-11-06 中国铁道科学研究院集团有限公司铁道建筑研究所 一种接枝抗氧剂分子的多元醇
BR112020004023A2 (pt) * 2017-09-12 2020-09-08 Sunregen Healthcare Ag uso de um composto e composição farmacêutica ou suplemento nutricional
UY37920A (es) * 2017-10-05 2019-03-29 Receptor Life Sciences Inc Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
CN111163790A (zh) * 2017-10-05 2020-05-15 受体控股公司 生物利用率提高的草药组合物
KR102054401B1 (ko) 2018-03-26 2019-12-10 주식회사 엔지켐생명과학 1,2-디아실글리세롤 화합물, 그 제조방법 및 이를 유효성분으로 함유하는 면역조절제
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques
UY38480A (es) 2018-11-19 2020-06-30 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides
US20220416362A1 (en) * 2019-10-31 2022-12-29 Zeon Corporation Functional layer for electrochemical device and method for manufacturing the same, separator with functional layer for electrochemical device and method for manufacturing the same, and electrochemical device and method for manufacturing the same
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20240415798A1 (en) * 2021-10-18 2024-12-19 Enzychem Lifesciences Corporation Compositions and methods for treating mucositis
JP2025514928A (ja) * 2022-04-21 2025-05-13 メルク・シャープ・アンド・ドーム・エルエルシー 凝集した結晶質中鎖脂肪酸ナトリウム塩を調製するプロセス

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2006A (en) * 1841-03-16 Clamp for crimping leather
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US2008A (en) * 1841-03-18 Gas-lamp eok conducting gas pkom ah elevated buhner to one below it
US4528197A (en) * 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4703062A (en) * 1984-01-16 1987-10-27 Baxter Travenol Laboratories, Inc. Parenteral nutrition with medium and long chain triglycerides
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
US7307166B1 (en) * 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JPH02134326A (ja) * 1988-11-14 1990-05-23 Snow Brand Milk Prod Co Ltd 高度侵襲用経腸栄養剤
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
WO1992014480A1 (en) * 1991-02-22 1992-09-03 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
JP3132085B2 (ja) * 1991-09-06 2001-02-05 ウェルファイド株式会社 脂肪乳剤
JPH05163160A (ja) * 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US5214035A (en) * 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995030413A1 (en) 1994-05-10 1995-11-16 The Kitasato Institute Hematopoietic stem cell proliferation accelerator
US5470861A (en) * 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5733884A (en) * 1995-11-07 1998-03-31 Nestec Ltd. Enteral formulation designed for optimized wound healing
BR9611826A (pt) * 1995-11-28 1999-07-13 Braun Melsungen Ag Emulsões de lipído otimizadas quanto a hidrólise e seu uso
AUPN933396A0 (en) * 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) * 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
US6017531A (en) * 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
CA2303200A1 (en) 1997-09-04 1999-03-11 Brian C. Keller Oral liposomal delivery system
CA2311124A1 (en) * 1997-11-19 1999-05-27 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
EP1061932B1 (en) * 1997-11-20 2006-01-25 Gil Ja Jhon Pharmaceutical composition containing extracts of cervus nippon antlers having growth-stimulating activities of hematopoietic stem cells and megakaryocytes
WO1999045934A1 (fr) 1998-03-11 1999-09-16 Grelan Pharmaceutical Co., Ltd. Preparations entero-solubles effervescentes
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
CA2385989A1 (en) * 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
AU2001264079A1 (en) * 2000-06-14 2001-12-24 William Leslie Porter Lipids for modulating immune response
AU2001285765A1 (en) * 2000-06-20 2002-01-02 Nutrition Sciences Medium chain fatty acids applicable as antimicrobial agents
US6967028B2 (en) * 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
WO2002083120A2 (en) 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
AP2005003367A0 (en) 2003-02-07 2005-09-30 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis.
US6725510B1 (en) * 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
PL1648851T3 (pl) 2003-07-25 2007-09-28 Prometic Biosciences Inc Wytwarzanie soli średniołańcuchowych kwasów tłuszczowych z metalami
BRPI0515136A (pt) * 2004-09-03 2008-07-08 Prometic Biosciences Inc derivados de purinila substituìdos com atividade imunomoduladora e quimioprotetora, seus usos isolados ou com ácidos graxos ou glicerìdeos de comprimento de cadeia médio e respectivas composições
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
US7745488B2 (en) 2010-06-29
CY1107081T1 (el) 2012-10-24
US8487001B2 (en) 2013-07-16
EA200301131A1 (ru) 2004-04-29
JP6420089B2 (ja) 2018-11-07
IL195200A (en) 2011-11-30
US20100279959A1 (en) 2010-11-04
AP1740A (en) 2007-05-10
CA2763637A1 (en) 2002-10-24
DK1385498T3 (da) 2008-03-25
CA2763637C (en) 2016-08-23
CZ20032685A3 (cs) 2004-06-16
IL158322A0 (en) 2004-05-12
PL402948A1 (pl) 2013-05-13
AU2006201163B2 (en) 2006-10-05
MXPA03009436A (es) 2004-12-06
ZA200307778B (en) 2004-04-21
NZ528690A (en) 2005-08-26
AP2003002888A0 (en) 2003-12-31
EP1900364B1 (en) 2013-09-25
SK12772003A3 (sk) 2004-07-07
AU2006201163A1 (en) 2006-04-13
EP1385498A2 (en) 2004-02-04
WO2002083120A3 (en) 2003-05-22
CA2444463C (en) 2012-03-20
PL222876B1 (pl) 2016-09-30
PT1385498E (pt) 2007-12-14
NO20034644L (no) 2003-11-25
HUP0303817A3 (en) 2009-10-28
BR0208984A (pt) 2004-06-29
IL195200A0 (en) 2009-08-03
EA007322B1 (ru) 2006-08-25
ES2439738T3 (es) 2014-01-24
JP5657879B2 (ja) 2015-01-21
PL223348B1 (pl) 2016-10-31
AU2002308456B2 (en) 2005-12-22
IL158322A (en) 2011-09-27
EP1900364A3 (en) 2009-09-23
PL366435A1 (en) 2005-01-24
OA12506A (en) 2006-05-29
EP1385498B1 (en) 2007-11-21
JP2004525957A (ja) 2004-08-26
NO335105B1 (no) 2014-09-15
CA2444463A1 (en) 2002-10-24
HUP0303817A2 (hu) 2004-03-01
KR20030096323A (ko) 2003-12-24
DK1900364T3 (da) 2014-01-13
JP2014231519A (ja) 2014-12-11
JP5026655B2 (ja) 2012-09-12
PT1900364E (pt) 2013-12-19
BG108280A (bg) 2004-09-30
BG66418B1 (bg) 2014-03-31
NZ541140A (en) 2006-11-30
SI1385498T1 (sl) 2008-04-30
EE200300510A (et) 2004-02-16
EP1900364A2 (en) 2008-03-19
ES2295397T3 (es) 2008-04-16
CN1633286A (zh) 2005-06-29
TNSN03089A1 (en) 2005-12-23
JP2010053135A (ja) 2010-03-11
NO20034644D0 (no) 2003-10-17
WO2002083120A2 (en) 2002-10-24
US20040147599A1 (en) 2004-07-29
DE60223670D1 (de) 2008-01-03
CZ305273B6 (cs) 2015-07-15

Similar Documents

Publication Publication Date Title
DE60223670T2 (de) Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
DE60037277T2 (de) Adenosinrezeptor-agonist oder antagonist enthaltende pharmazeutische zusammensetzungen
DE60202278T2 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
DE69318033T2 (de) Antitumorzusammensetzungen enthaltend taxanderivate
DE3853067T2 (de) Verfahren zur inhibierung der wirkung von aus leukozyten abgeleiteten cytokinen.
DE60011391T2 (de) Verfahren und zusammensetzungen zur erhöhung der anzahl weisser blutzellen
DE69431620T2 (de) Zusammensetzungen für die anwendung in menschlicher therapie, charakterisiert durch die assoziation eines muramylpeptids mit einem cytokin
DE60130023T2 (de) Behandlung der nebenwirkungen von statinen
DE60121440T2 (de) Zusammensetzung zur Krebsbehandlung, welche ein antineoplastisches Mittel und einen PDE4-Inhibitor enthält
KR101120775B1 (ko) 적혈구생성의 자극제로서의 중쇄 지방산, 글리세리드 및유사체
DE60118889T2 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE69713485T2 (de) Medikamente für die Behandlung oder Vorbeugung von Thrombocytopenie
DE69328558T2 (de) Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
DE69929464T2 (de) Zyklische polyamine zur behandlung der thrombozytopenie
EP0359981A1 (de) Pharmazeutische Kombinationspräparate und deren Verwendung als antineoplastische Arzneimittel
DE69634982T2 (de) Verfahren zur steigerung von hematopoietischen zellen
DE69733694T2 (de) Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
DE69634074T2 (de) Thiole zur Förderung des Wachstums von Hömatopoietischen Vorläuferzellen
EP0453898A2 (de) Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Ischämien und deren Folgen
DE69123361T2 (de) Verwendung von interleukin-4 zur behandlung der festen tumoren
DE69812100T2 (de) Adenosin enthaltendes arzneimittel
DE3854726T2 (de) Synergistische Wechselwirkung von Interleukin-2 und doppelsträngiger RNS.
DE69034076T2 (de) Verwendung von Human-Beta-Interferon zur Herstellung von pharmazeutischen Zusammensetzungen zur Behandlung von chronischer Myeloidleukämie
DE69001686T2 (de) Behandlung von leukozytstoerungen mit gm-csf.
DE3875859T2 (de) Zubereitungen zur verbesserung der adcc-therapien.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: GAGNON, LYNE, LAVAL, QUEBEC H7M 3E5, CA

Inventor name: BARABE, JEAN, MONTREAL, QUEBEC H1X 3J1, CA

Inventor name: LAURIN, PIERRE, MONTREAL, QUEBEC H4P 2L7, CA

Inventor name: PENNEY, CHRISTOPHER, PIERRFONDS, QUEBEC H8Z 3K, CA

Inventor name: ZACHARIE, BOULOS, LAVAL, QUEBEC H7P 5Y3, CA

8364 No opposition during term of opposition